Personalis, Inc. Earnings Recaps
Q3 2025
Nov 5, 2025
Personalis achieved significant growth in Q3 2025 with a 364% year-over-year increase in clinical tests, reflecting strong demand for its ultrasensitive NeXT Personal test, while adjusting revenue guidance due to biopharma project timing variability.
Key takeaways
- Revenue of $14.5 million surpassed expectations, driven by 4,388 clinical tests delivered in the quarter.
- Growth in clinical adoption highlighted by over 700 physicians now ordering NeXT Personal.
- Submitted additional coverage application for lung cancer, with three dossiers currently under review by MolDX.
- Despite uneven biopharma spending, underlying demand for MRD technology remains strong, supporting long-term growth strategy.
- Full-year revenue guidance adjusted to $68 million - $73 million, reflecting project timing volatility rather than demand changes.